Novozymes Biopharma has announced its new collaboration with Almac to provide a combined service for drug development applications in drug targeting and pharmacokinetic improvements.
Drug developers will now be able to utilize Almac’s manufacturing assets and protein conjugation capability to link Novozymes’ Recombumin Flex technology to their peptide and small molecule drugs. This technology has been shown to improve pharmacokinetics and drug targeting in oncology and rheumatoid arthritis.
Clients will benefit from the continuity of service provision throughout clinical development. Collaborations with commercial partners have already begun and will continue to expand in early 2014.
The focal point of this collaboration is Novozymes’ Recombumin Flex technology, which complements Almac’s capabilities in peptide and small molecule manufacutring. Novozymes’ modified amino acid sequence of human albumin has higher receptor affinity, thereby prolonging half-life and improving drug targeting.
Source: Almac
